Drug intelligence / Profile preview

mastalgia-oil + tamoxifen

Development stage: Unknown
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Topical, Oral

Overview

A combination treatment consisting of mastalgia-oil (topical application) and tamoxifen (oral administration) being studied for the treatment of mastalgia (breast pain). Tamoxifen is a selective estrogen receptor modulator that competitively inhibits estrogen binding to its receptor, which helps reduce breast pain, particularly cyclical mastalgia. The mastalgia-oil component appears to be a topical formulation, though its specific composition is not detailed in the available information.

Targets

ESR2 (ERβ)ESR1 (ERα)

Beyond the preview

Go deeper on mastalgia-oil + tamoxifen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mastalgia-oil + tamoxifen.

Explore the full profile